$FPRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in FIVE PRIME THERAPEUTICS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in FIVE PRIME THERAPEUTICS, INC.. Get notifications about new insider transactions in FIVE PRIME THERAPEUTICS, INC. for free.
Page: < prev 1 2 3 4 5 5 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 21 2020 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Chief Executive Off ... | Option Exercise | A | 5.31 | 40,868 | 217,009 | 40,868 | |
Jan 21 2020 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Chief Executive Off ... | Option Exercise | A | 5.31 | 40,868 | 217,009 | 40,868 | |
Dec 26 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 32,606 | 132,054 | 536,608 | 504 K to 536.6 K (+6.47 %) |
Dec 26 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 201,096 | 814,439 | 3,078,989 | 2.9 M to 3.1 M (+6.99 %) |
Dec 26 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 281,318 | 1,139,338 | 3,929,792 | 3.6 M to 3.9 M (+7.71 %) |
Dec 20 2019 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Interim CEO | Option Exercise | A | 3.94 | 49,552 | 195,235 | 49,552 | |
Dec 11 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.02 | 2,397 | 9,630 | 504,002 | 501.6 K to 504 K (+0.48 %) |
Dec 11 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.02 | 18,729 | 75,244 | 2,877,893 | 2.9 M to 2.9 M (+0.66 %) |
Dec 11 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.02 | 113,874 | 457,489 | 3,648,474 | 3.5 M to 3.6 M (+3.22 %) |
Dec 04 2019 | FPRX | FIVE PRIME THERAPE ... | BERGER FRANKLIN M | Director | Sell | S | 4.00 | 47,890 | 191,560 | 5,000 | 52.9 K to 5 K (-90.55 %) |
Dec 04 2019 | FPRX | FIVE PRIME THERAPE ... | BERGER FRANKLIN M | Director | Sell | S | 3.92 | 32,090 | 125,793 | 52,890 | 85 K to 52.9 K (-37.76 %) |
Nov 27 2019 | FPRX | FIVE PRIME THERAPE ... | Smith David V | Executive Vice Pres ... | Payment of Exercise | F | 3.77 | 6,611 | 24,923 | 33,389 | 40 K to 33.4 K (-16.53 %) |
Nov 26 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.40 | 81,857 | 278,322 | 501,605 | 419.7 K to 501.6 K (+19.50 %) |
Nov 26 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.40 | 462,056 | 1,571,037 | 2,859,164 | 2.4 M to 2.9 M (+19.28 %) |
Nov 26 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.40 | 576,097 | 1,958,787 | 3,534,600 | 3 M to 3.5 M (+19.47 %) |
Nov 20 2019 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Interim CEO | Option Exercise | A | 3.23 | 50,367 | 162,685 | 50,367 | |
Nov 07 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 70,921 | 283,684 | 419,748 | 348.8 K to 419.7 K (+20.33 %) |
Nov 07 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 400,470 | 1,601,880 | 2,397,108 | 2 M to 2.4 M (+20.06 %) |
Nov 07 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 496,721 | 1,986,884 | 2,958,503 | 2.5 M to 3 M (+20.18 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 504 | 1,940 | 348,827 | 348.3 K to 348.8 K (+0.14 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 2,913 | 11,214 | 1,996,638 | 2 M to 2 M (+0.15 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.85 | 3,416 | 13,150 | 2,461,782 | 2.5 M to 2.5 M (+0.14 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.89 | 1,456 | 5,667 | 348,323 | 346.9 K to 348.3 K (+0.42 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.89 | 8,236 | 32,055 | 1,993,725 | 2 M to 2 M (+0.41 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.89 | 10,389 | 40,435 | 2,458,366 | 2.4 M to 2.5 M (+0.42 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.90 | 240 | 935 | 346,867 | 346.6 K to 346.9 K (+0.07 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.90 | 1,133 | 4,415 | 1,985,489 | 2 M to 2 M (+0.06 %) |
Oct 31 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.90 | 1,027 | 4,002 | 2,447,977 | 2.4 M to 2.4 M (+0.04 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 2,155 | 8,075 | 346,627 | 344.5 K to 346.6 K (+0.63 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 12,899 | 48,336 | 1,984,356 | 2 M to 2 M (+0.65 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 15,728 | 58,938 | 2,446,950 | 2.4 M to 2.4 M (+0.65 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 1,629 | 6,100 | 344,472 | 342.8 K to 344.5 K (+0.48 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 57,723 | 216,155 | 1,971,457 | 1.9 M to 2 M (+3.02 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 76,036 | 284,732 | 2,431,222 | 2.4 M to 2.4 M (+3.23 %) |
Oct 25 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 3,200 | 11,986 | 2,355,186 | 2.4 M to 2.4 M (+0.14 %) |
Oct 21 2019 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Interim CEO | Option Exercise | A | 3.99 | 46,939 | 187,287 | 46,939 | |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Interim CEO | Option Exercise | A | 3.79 | 34,451 | 130,569 | 34,451 | |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.68 | 4,689 | 17,270 | 342,843 | 338.2 K to 342.8 K (+1.39 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.68 | 24,716 | 91,029 | 1,913,734 | 1.9 M to 1.9 M (+1.31 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.68 | 31,007 | 114,199 | 2,351,986 | 2.3 M to 2.4 M (+1.34 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 24,425 | 91,594 | 338,154 | 313.7 K to 338.2 K (+7.79 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 14,242 | 53,382 | 313,729 | 299.5 K to 313.7 K (+4.76 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 138,609 | 519,784 | 1,889,018 | 1.8 M to 1.9 M (+7.92 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 80,821 | 302,933 | 1,750,409 | 1.7 M to 1.8 M (+4.84 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 168,640 | 632,400 | 2,320,979 | 2.2 M to 2.3 M (+7.84 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.75 | 98,333 | 368,572 | 2,152,339 | 2.1 M to 2.2 M (+4.79 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 991 | 3,704 | 299,487 | 298.5 K to 299.5 K (+0.33 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 7,314 | 27,336 | 1,669,588 | 1.7 M to 1.7 M (+0.44 %) |
Oct 08 2019 | FPRX | FIVE PRIME THERAPE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.74 | 7,695 | 28,760 | 2,054,006 | 2 M to 2.1 M (+0.38 %) |
Sep 04 2019 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Director | Payment of Exercise | F | 5.43 | 7,024 | 38,140 | 455,336 | 462.4 K to 455.3 K (-1.52 %) |
Sep 04 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Payment of Exercise | F | 5.43 | 3,306 | 17,952 | 42,057 | 45.4 K to 42.1 K (-7.29 %) |
Sep 04 2019 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Payment of Exercise | F | 5.43 | 2,811 | 15,264 | 82,248 | 85.1 K to 82.2 K (-3.30 %) |
Sep 04 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | EVP and Chief Medic ... | Payment of Exercise | F | 5.43 | 496 | 2,693 | 44,298 | 44.8 K to 44.3 K (-1.11 %) |
Aug 22 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | EVP and Chief Medic ... | Option Exercise | A | 5.78 | 20,000 | 115,600 | 20,000 | |
Aug 22 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | EVP and Chief Medic ... | Grant | A | 0.00 | 5,000 | 0 | 44,794 | 39.8 K to 44.8 K (+12.56 %) |
Jun 26 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | A | 0.00 | 124,420 | 0 | 124,420 | |
Jun 26 2019 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Option Exercise | A | 0.00 | 44,000 | 0 | 44,000 | |
Jun 26 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Option Exercise | A | 0.00 | 44,000 | 0 | 44,000 | |
Jun 26 2019 | FPRX | FIVE PRIME THERAPE ... | Smith David V | Executive Vice Pres ... | Option Exercise | A | 0.00 | 44,000 | 0 | 44,000 | |
Jun 25 2019 | FPRX | FIVE PRIME THERAPE ... | Lyons-Williams Lori | Director | Option Exercise | A | 6.30 | 25,000 | 157,500 | 25,000 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Director | Option Exercise | A | 6.09 | 15,000 | 91,350 | 15,000 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | SCHAFER CAROL | Director | Option Exercise | A | 6.09 | 1,250 | 7,613 | 1,250 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Director | Option Exercise | A | 6.09 | 15,000 | 91,350 | 15,000 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | BERGER FRANKLIN M | Director | Option Exercise | A | 6.09 | 15,000 | 91,350 | 15,000 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | Nicholson Garry A | Director | Option Exercise | A | 6.09 | 15,000 | 91,350 | 15,000 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | Jensen Peder | Director | Option Exercise | A | 6.09 | 15,000 | 91,350 | 15,000 | |
Jun 12 2019 | FPRX | FIVE PRIME THERAPE ... | Dhingra Kapil | Director | Option Exercise | A | 6.09 | 15,000 | 91,350 | 15,000 | |
Jun 10 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 5.54 | 11,357 | 62,918 | 0 | |
Jun 10 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 5.54 | 11,357 | 62,918 | 195,828 | 184.5 K to 195.8 K (+6.16 %) |
Jun 10 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 5.54 | 11,357 | 62,918 | 0 | |
Jun 10 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 5.54 | 11,357 | 62,918 | 195,828 | 184.5 K to 195.8 K (+6.16 %) |
May 16 2019 | FPRX | FIVE PRIME THERAPE ... | SCHAFER CAROL | Director | Option Exercise | A | 9.17 | 25,000 | 229,250 | 25,000 | |
May 16 2019 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Payment of Exercise | F | 9.17 | 620 | 5,685 | 30,533 | 31.2 K to 30.5 K (-1.99 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | A | 11.97 | 156,910 | 1,878,213 | 156,910 | |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Payment of Exercise | F | 11.95 | 2,462 | 29,421 | 218,445 | 220.9 K to 218.4 K (-1.11 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Grant | A | 0.00 | 25,844 | 0 | 220,907 | 195.1 K to 220.9 K (+13.25 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Option Exercise | A | 11.97 | 58,000 | 694,260 | 58,000 | |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Payment of Exercise | F | 11.95 | 1,118 | 13,360 | 31,153 | 32.3 K to 31.2 K (-3.46 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Grant | A | 0.00 | 10,000 | 0 | 32,271 | 22.3 K to 32.3 K (+44.90 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Option Exercise | A | 11.97 | 58,000 | 694,260 | 58,000 | |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 11.95 | 1,177 | 14,065 | 39,794 | 41 K to 39.8 K (-2.87 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Grant | A | 0.00 | 10,000 | 0 | 40,971 | 31 K to 41 K (+32.29 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Option Exercise | A | 11.97 | 58,000 | 694,260 | 58,000 | |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Payment of Exercise | F | 11.95 | 1,194 | 14,268 | 82,955 | 84.1 K to 83 K (-1.42 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Grant | A | 0.00 | 10,000 | 0 | 84,149 | 74.1 K to 84.1 K (+13.49 %) |
Feb 27 2019 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Director | Payment of Exercise | F | 11.95 | 926 | 11,066 | 461,360 | 462.3 K to 461.4 K (-0.20 %) |
Feb 07 2019 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Payment of Exercise | F | 11.43 | 2,996 | 34,244 | 74,149 | 77.1 K to 74.1 K (-3.88 %) |
Feb 07 2019 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 11.43 | 3,196 | 36,530 | 30,971 | 34.2 K to 31 K (-9.35 %) |
Feb 07 2019 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Director | Payment of Exercise | F | 11.43 | 3,144 | 35,936 | 462,286 | 465.4 K to 462.3 K (-0.68 %) |
Feb 07 2019 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Payment of Exercise | F | 11.43 | 2,996 | 34,244 | 195,063 | 198.1 K to 195.1 K (-1.51 %) |
Jan 11 2019 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Nov 27 2018 | FPRX | FIVE PRIME THERAPE ... | Smith David V | Executive Vice Pres ... | Option Exercise | A | 12.47 | 185,000 | 2,306,950 | 185,000 | |
Nov 27 2018 | FPRX | FIVE PRIME THERAPE ... | Smith David V | Executive Vice Pres ... | Grant | A | 0.00 | 40,000 | 0 | 40,000 | 0 to 40 K |
Nov 13 2018 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Executive Chairman | Option Exercise | M | 4.56 | 91,217 | 415,950 | 0 | |
Nov 13 2018 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Executive Chairman | Buy | M | 4.56 | 91,217 | 415,950 | 465,430 | 374.2 K to 465.4 K (+24.38 %) |
Oct 02 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Payment of Exercise | F | 13.92 | 954 | 13,280 | 196,966 | 197.9 K to 197 K (-0.48 %) |
Oct 02 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Grant | A | 0.00 | 1,775 | 0 | 197,920 | 196.1 K to 197.9 K (+0.90 %) |
Oct 02 2018 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Payment of Exercise | F | 13.92 | 954 | 13,280 | 77,145 | 78.1 K to 77.1 K (-1.22 %) |
Oct 02 2018 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Grant | A | 0.00 | 1,923 | 0 | 78,099 | 76.2 K to 78.1 K (+2.52 %) |
Oct 02 2018 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 13.92 | 1,906 | 26,532 | 34,167 | 36.1 K to 34.2 K (-5.28 %) |
Oct 02 2018 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Grant | A | 0.00 | 3,844 | 0 | 36,073 | 32.2 K to 36.1 K (+11.93 %) |
Sep 27 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 584 | 6,506 | 31,595 | |
Sep 27 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 584 | 6,506 | 196,145 | 195.6 K to 196.1 K (+0.30 %) |
Sep 25 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 32,179 | |
Sep 25 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 195,561 | 195.1 K to 195.6 K (+0.26 %) |
Sep 20 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 32,679 | |
Sep 20 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 195,061 | 194.6 K to 195.1 K (+0.26 %) |
Sep 18 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 33,179 | |
Sep 18 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 194,561 | 194.1 K to 194.6 K (+0.26 %) |
Sep 12 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 1,000 | 11,140 | 33,679 | |
Sep 12 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 1,000 | 11,140 | 194,061 | 193.1 K to 194.1 K (+0.52 %) |
Sep 06 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 34,679 | |
Sep 06 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 193,061 | 192.6 K to 193.1 K (+0.26 %) |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 35,179 | |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 192,561 | 192.1 K to 192.6 K (+0.26 %) |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Payment of Exercise | F | 14.00 | 3,306 | 46,284 | 192,061 | 195.4 K to 192.1 K (-1.69 %) |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Williams Lewis T | Executive Chairman | Payment of Exercise | F | 14.00 | 7,024 | 98,336 | 374,213 | 381.2 K to 374.2 K (-1.84 %) |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Sarena Francis Willard | Chief Strategy Offi ... | Payment of Exercise | F | 14.00 | 2,810 | 39,340 | 76,177 | 79 K to 76.2 K (-3.56 %) |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Payment of Exercise | F | 14.00 | 2,479 | 34,706 | 22,271 | 24.8 K to 22.3 K (-10.02 %) |
Sep 05 2018 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 14.00 | 496 | 6,944 | 32,229 | 32.7 K to 32.2 K (-1.52 %) |
Aug 28 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 35,679 | |
Aug 28 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 195,367 | 194.9 K to 195.4 K (+0.26 %) |
Aug 23 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 36,179 | |
Aug 23 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 194,867 | 194.4 K to 194.9 K (+0.26 %) |
Aug 22 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 36,679 | |
Aug 22 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 194,367 | 193.9 K to 194.4 K (+0.26 %) |
Aug 21 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 37,179 | |
Aug 21 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 193,867 | 193.4 K to 193.9 K (+0.26 %) |
Aug 16 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 37,679 | |
Aug 16 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 193,367 | 192.9 K to 193.4 K (+0.26 %) |
Aug 14 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 38,179 | |
Aug 14 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 192,867 | 192.4 K to 192.9 K (+0.26 %) |
Aug 08 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 38,679 | |
Aug 08 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | M | 11.14 | 500 | 5,570 | 39,179 | |
Aug 08 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 192,367 | 191.9 K to 192.4 K (+0.26 %) |
Aug 08 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Buy | M | 11.14 | 500 | 5,570 | 191,867 | 191.4 K to 191.9 K (+0.26 %) |
Jun 26 2018 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 17.38 | 1,240 | 21,551 | 32,725 | 34 K to 32.7 K (-3.65 %) |
Jun 26 2018 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 17.38 | 1,240 | 21,551 | 32,725 | 34 K to 32.7 K (-3.65 %) |
Jun 12 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Gift | G | 0.00 | 845 | 0 | 14,238 | 15.1 K to 14.2 K (-5.60 %) |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Option Exercise | A | 17.27 | 22,500 | 388,575 | 22,500 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | Irving Bryan | EVP, Chief Scientif ... | Grant | A | 0.00 | 3,750 | 0 | 24,750 | 21 K to 24.8 K (+17.86 %) |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | RINGO WILLIAM R | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | Nicholson Garry A | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | MCDADE MARK | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | Jensen Peder | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | Dhingra Kapil | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | BERGER FRANKLIN M | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
May 14 2018 | FPRX | FIVE PRIME THERAPE ... | Gujrathi Sheila | Director | Option Exercise | A | 17.27 | 10,000 | 172,700 | 10,000 | |
Mar 22 2018 | FPRX | FIVE PRIME THERAPE ... | Collins Helen Louise | SVP and Chief Medic ... | Payment of Exercise | F | 16.26 | 827 | 13,447 | 33,965 | 34.8 K to 34 K (-2.38 %) |
Feb 28 2018 | FPRX | FIVE PRIME THERAPE ... | Knickerbocker Aron Marc | President & CEO | Option Exercise | A | 18.69 | 83,070 | 1,552,578 | 83,070 |